Published in Hepatology on January 01, 1996
Gallstones in patients with liver cirrhosis: incidence, etiology, clinical and therapeutical aspects. World J Gastroenterol (2014) 0.82
Gallstones in Patients with Chronic Liver Diseases. Biomed Res Int (2017) 0.75
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials (1985) 6.22
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res (1999) 4.74
Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. N Engl J Med (1994) 2.94
Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? Aliment Pharmacol Ther (2012) 2.68
Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer (1998) 2.52
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Detection of Aspergillus species DNA in bronchoalveolar lavage samples by competitive PCR. J Clin Microbiol (1995) 2.28
Excess weight risk factor for alcoholic liver disease. Hepatology (1997) 2.22
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology (1999) 2.11
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med (1995) 2.06
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med (1994) 2.05
Detection of Toxoplasma gondii by competitive DNA amplification of bronchoalveolar lavage samples. J Infect Dis (1993) 2.04
Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology (1995) 2.00
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 1.97
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol (2001) 1.88
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat (2007) 1.86
Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology (1997) 1.84
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res (1998) 1.80
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem (1999) 1.74
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J Autoimmun (1991) 1.71
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat (2002) 1.71
A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology (1991) 1.70
Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut (2005) 1.65
Appropriateness of liver biopsy. Can J Gastroenterol (2000) 1.65
Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut (2008) 1.63
Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet (2003) 1.62
Modeling the hepatitis C virus epidemic in France. Hepatology (1999) 1.61
Natural history of HCV infection. Baillieres Best Pract Res Clin Gastroenterol (2000) 1.61
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther (2014) 1.60
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice. Clin Diagn Lab Immunol (2001) 1.58
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57
Trends in primary liver cancer. Lancet (1998) 1.56
A two-centre, randomized, double-blind trial of ornithine oxoglutarate in 194 elderly, ambulatory, convalescent subjects. Age Ageing (1994) 1.56
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut (2009) 1.56
Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol (1999) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Pancreatic lesions in AIDS. Lancet (1987) 1.55
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res (2000) 1.53
A 5' splice-region G----C mutation in exon 1 of the human beta-globin gene inhibits pre-mRNA splicing: a mechanism for beta+-thalassemia. Proc Natl Acad Sci U S A (1989) 1.48
TaqMan PCR-based gene dosage assay for predictive testing in individuals from a cancer family with INK4 locus haploinsufficiency. Clin Chem (1999) 1.48
Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol (1999) 1.47
Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res (2001) 1.45
Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis (1999) 1.45
Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut (1999) 1.44
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med (1992) 1.44
Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther (2002) 1.43
Endoscopic Nd-YAG laser therapy as palliative treatment for esophageal and cardial cancer. Parameters affecting long-term outcome. Dig Dis Sci (1990) 1.43
[CagA status and virulence of Helicobacter pylori strains. Results of a French multicentric prospective study]. Gastroenterol Clin Biol (2001) 1.42
PCR enzyme-linked immunosorbent assay for diagnosis of leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol (1996) 1.42
Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology (1995) 1.41
Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD. EMBO J (1991) 1.40
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38
Endoscopic laser therapy for duodenal villous adenoma. Dig Dis Sci (1989) 1.38
The course of hepatitis C virus infection after liver transplantation. Hepatology (1994) 1.38
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology (1998) 1.37